A real-world study of active vitamin D as a prognostic marker in patients with sarcoma.

PURPOSE

The assessment of sarcoma during clinical practice is primarily based on imaging examination, with no effective biomarkers available. Although it has been established that 1,25(OH)D is abnormally expressed in patients with sarcoma, it remains unclear whether 1,25(OH)D level could be used as an evaluation marker in these patient population.

METHODS

This real-world study investigated 1,25(OH)D level and its association with clinical features in sarcoma patients. Data on 1,25(OH)D, parathyroid hormone, calcium, and calcitonin were collected from 331 patients with sarcoma, while the imaging results and the variation in 1,25(OH)D among 213 patients with sarcoma before and after treatment was further analyzed.

RESULTS

We found that the serum 1,25(OH)D level was predominantly decreased in patients with sarcoma, with a mean of 45.68 nmol/L. 1,25(OH)D was significantly correlated with the gender and age of sarcoma patients, with more substantial reductions in women and younger patients. Among sarcoma patients, those with progressive disease exhibited a 7.08 nmol/L (-13.73%) decrease in serum 1,25(OH)D levels compared to baseline, while patients with non-progressive disease showed a 1.11 nmol/L (+ 7.0%) increase.

CONCLUSION

The variation of serum 1,25(OH)D can predict the disease status of patients with sarcoma. Decreased serum 1,25(OH)D levels are indicative of disease progression in sarcoma patients, suggesting its potential for application as a prognostic marker for disease assessment in this patient population.